Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
HER-2 L755S
Cancer:
Colorectal Cancer
Drug:
Vectibix (panitumumab)
(
EGFR inhibitor
)
Direction:
Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
New
Source:
Cancer Discov
Title:
HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
Excerpt:
Five HER2 mutations were tested in NCI-H508 cells, and all mutations produced resistance to cetuximab and panitumumab.
DOI:
10.1158/2159-8290.CD-14-1211
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login